Analysis Of Overall Survival (OS) In The Context Of Cross-Over From Placebo To Lenalidomide And The Incidence Of Second Primary Malignancies (SPM) In The Phase III Study Of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) CALGB (Alliance) ECOG BMT-CTN 100104
- Citation:
- Clin Lymphoma Myeloma Leuk vol 13 (suppl 1) S28
- Meeting Instance:
- IMW 2013
- Year:
- 2013
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2660
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- P. Mccarthy K. Owzar C. Hofmeister P. Richardson H. Hassoun E. Stadtmauer S. Giralt D. Hurd M. Qazilbash B. Mcclune M. Pasquini V. Hars C. Jiang J. Postiglione M. Kelly L. Bressler S. Devine K. Anderson C. Linker
- Networks:
- Study
- CALGB-100104
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: